Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application-Reference-Cited by-同舟云学术

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

Published:2016-12-22 Issue:9 Volume:8 Page:16052-16074
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Chae Young Kwang¹²³,Ranganath Keerthi³,Hammerman Peter S.⁴,Vaklavas Christos⁵,Mohindra Nisha¹²³,Kalyan Aparna¹²³,Matsangou Maria¹²³,Costa Ricardo¹,Carneiro Benedito¹²³,Villaflor Victoria M.¹²³,Cristofanilli Massimo¹²³,Giles Francis J.¹²³

Affiliation:

1. Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA

2. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

3. Northwestern University Feinberg School of Medicine, Chicago, IL, USA

4. Dana Farber Cancer Institute, Boston, MA, USA

5. Division of Hematology Oncology, University of Alabama Birmingham, Birmingham, AL, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 256 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer;European Journal of Medicinal Chemistry;2024-11

2. A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis;Drug Resistance Updates;2024-09

3. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies;Cancer Communications;2024-08-19

4. Early Optical Coherence Tomography Signs of Erdafitinib-Induced Retinopathy;Cureus;2024-08-15

5. Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer;Frontiers in Oncology;2024-07-17